相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study
Xiaoming Jia et al.
CIRCULATION (2019)
Negative Risk Markers for Cardiovascular Events in the Elderly
Martin Bodtker Mortensen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
One-year in vitro stability of cardiac troponins and galectin-3 in different sample types
Margot Egger et al.
CLINICA CHIMICA ACTA (2018)
Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults
Anum Saeed et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
Navin Suthahar et al.
THERANOSTICS (2018)
Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
Anahita Ghorbani et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population
Tasnim F. Imran et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity The Atherosclerosis Risk in Communities (ARIC) Study
Chiadi E. Ndumele et al.
CIRCULATION (2016)
Serial galectin-3 and future cardiovascular disease in the general population
A. Rogier van der Velde et al.
HEART (2016)
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice
Giuseppe Vergaro et al.
HYPERTENSION (2016)
Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND
A. Rogier van der Velde et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites
John W. McEvoy et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Galectin-3 Predicts Long-Term Cardiovascular Death in High-Risk Patients With Coronary Artery Disease
Giuseppe Maiolino et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension
Ernesto Martinez-Martinez et al.
HYPERTENSION (2015)
Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort
Annika Jagodzinski et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study
Lori B. Daniels et al.
AMERICAN HEART JOURNAL (2014)
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
David C. Goff et al.
CIRCULATION (2014)
Plasma galectin 3 and heart failure risk in the Physicians' Health Study
Luc Djousse et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis
Laurent Calvier et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis
Lili Yu et al.
CIRCULATION-HEART FAILURE (2013)
Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure Data From CORONA and COACH
A. Rogier van der Velde et al.
CIRCULATION-HEART FAILURE (2013)
Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Risk-The Atherosclerosis Risk in Communities Study
Vijay Nambi et al.
CLINICAL CHEMISTRY (2013)
Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice
Alison C. MacKinnon et al.
GLYCOBIOLOGY (2013)
Troponin T, N-Terminal Pro-B-Type Natriuretic Peptide, and Incidence of Stroke The Atherosclerosis Risk in Communities Study
Aaron R. Folsom et al.
STROKE (2013)
Prediction of Incident Heart Failure in General Practice The Atherosclerosis Risk in Communities (ARIC) Study
Sunil K. Agarwal et al.
CIRCULATION-HEART FAILURE (2012)
The fibrosis marker galectin-3 and outcome in the general population
R. A. de Boer et al.
JOURNAL OF INTERNAL MEDICINE (2012)
Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community
Jennifer E. Ho et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study
Justin T. Saunders et al.
CIRCULATION (2011)
Several methods to assess improvement in risk prediction models: Extension to survival analysis
Lloyd E. Chambless et al.
STATISTICS IN MEDICINE (2011)
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin
Yun-He Liu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2009)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice
Maurice Nachtigal et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Differences in the Incidence of Congestive Heart Failure by Ethnicity - The Multi-Ethnic Study of Atherosclerosis
Hossein Bahrarni et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction
Marianna Papaspyridonos et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction
UC Sharma et al.
CIRCULATION (2004)
分享论文
